Skip to content

Folinic acid for autism

Evaluation of the efficacy of oral Folinic acid supplementation in children with Autism Spectrum disorders: a randomized double blind, placebo controlled trial - FIAT

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/034901
Enrollment
80
Registered
2021-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F840- Autistic disorder

Interventions

Intervention1: Oral Folinic acid: Participants in one arm will receive Folinic acid orally at a dose of 2 mg/kg/day (or maximum 50 mg/day) and participants in other arm will receive a placebo formulat

Sponsors

Indian Council of Medical Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Satisfying DSM V criteria for autism 2. Unchanged antipsychotic medication, complementary, traditional, behavioral and education therapy 8 weeks prior to enrollment 3. Intention to maintain ongoing therapies constant throughout the trial

Exclusion criteria

Exclusion criteria: 1. Uncontrolled gastroesophageal reflux 2. History of liver or kidney disease; 3. Receiving drugs known to affect folate metabolism 4.Well-defined genetic syndromes or genetic mutations known to significantly affect folate-associated pathways; 5. A clinical seizure within the last 6 months

Design outcomes

Primary

MeasureTime frame
Change in Childhood Autism Rating Scale (CARS)Timepoint: At 0 week and after 24 weeks

Secondary

MeasureTime frame
Childhood Sleep Habits QuestionnaireTimepoint: At 0 weeks and after 24 weeks

Countries

India

Contacts

Public ContactPrateek Kumar Panda

AIIMS, Rishikesh

drprateekpanda@gmail.com9650149735

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 6, 2026